Vanguard Capital Management filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a position of 9,086,791 shares of common stock in Xeris Biopharma Holdings Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported beneficial ownership of 9,086,791 shares of Xeris Biopharma Holdings Inc common stock.
  • Percent of class: The reported position represents 4.98% of the outstanding class of common stock.
  • Sole dispositive power: Vanguard Capital Management holds sole power to dispose of all 9,086,791 shares.
  • Sole voting power: Sole voting power is reported for 1,376,435 shares, with shared voting power of 0.
  • Event date: The triggering event date for this filing is September 30, 2026.
  • Affiliates included: The filing encompasses securities attributed to Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd.

Vanguard Capital Management Discloses Amended Stake in Xeris Biopharma

According to the filing, Vanguard Capital Management, organized in Pennsylvania and headquartered at 100 Vanguard Blvd, Malvern, PA 19355, submitted Amendment No. 1 to its beneficial ownership statement covering common stock of Xeris Biopharma Holdings Inc, a biopharmaceutical company with principal executive offices at 180 North LaSalle Street, Suite 1800, Chicago, IL 60601. The filing identifies Vanguard Capital Management as an investment adviser, classified as type "IA" under the relevant reporting instructions.

The filing reports that Vanguard Capital Management holds sole dispositive power over the full 9,086,791-share position, while sole voting power extends to only 1,376,435 of those shares. Shared voting power and shared dispositive power are each reported as 0. The filing states that the securities were acquired and are held in the ordinary course of business and, according to the certification, "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The statement also notes that the reported position encompasses securities held by Vanguard funds and managed accounts, including investment companies registered under the Investment Company Act of 1940. The filing specifies that no single other person's interest in the reported securities exceeds 5% of the class. Item 5 of the filing confirms that the aggregate position represents ownership of 5 percent or less of the class. The document was signed by My Trieu-Gatt, Authorized Signatory and Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Capital Management filed an amended Schedule 13G disclosing beneficial ownership of 9,086,791 shares, or 4.98%, of Xeris Biopharma Holdings Inc common stock (CUSIP 98422E103), with the triggering event dated September 30, 2026.